Figure 4.

AEG1 silencing inhibits the PD-L1 and EGFR expression in HCC.

Notes: (A) There is no difference of PD-L1 and EGFR messenger RNA expression between HCC tissues and normal tissues. (B) qRT-PCR assay and Western blot assay to measure PD-L1 mRNA and protein levels when AEG1 was down-regulated, and that the siRNA efficiency of AEG1 was most marked at the 744 and 1883 sites in HCC cells. (C) qRT-PCR assay and Western blot assay to measure EGFR mRNA and protein levels when AEG1 was down-regulated, and that the siRNA efficiency of AEG‐1 was most marked at the 744 and 1883 sites in HCC cells. (D) Luciferase assay showing activity for co-transfection of AEG1 and PDL1 promoter vector in HCC cells (**p < 0.01). (E) Luciferase assay showing activity for co-transfection of AEG1 and EGFR promoter vector in HCC cells (**p < 0.01; *p < 0.05).

Abbreviations: HCC, hepatocellular carcinoma; MU, mutant; WT, wild-type; qRT-PCR, quantitative real-time PCR; NC, negative control.